Discovery of a new hidden mechanism behind high blood pressure
Researchers from medical institutions in Australia and Singapore have discovered a new hidden biological mechanism that plays a key role in the development of high blood pressure, a finding that promises to revolutionize the understanding and treatment of chronic hypertension.
High blood pressure is one of the most prevalent chronic diseases worldwide, affecting approximately 1.28 billion adults, and represents a major risk factor for heart disease, stroke, and kidney failure.
The researchers found that resolution pathways—biological mechanisms that help the immune system terminate inflammatory responses in a timely manner—may be more significant in the progression of high blood pressure than previously thought. Under normal conditions, these pathways extinguish inflammation after the trigger has been removed. However, when these mechanisms are disrupted, low-grade chronic inflammation persists, leading to arterial stiffness and long-term high blood pressure.
The research team did not stop at identifying this mechanism; they also tested an experimental drug compound known as “17b,” yielding promising results that suggest the potential for developing a new class of medications to treat hypertension. This compound was designed to activate specific receptors on immune cells, thereby stimulating the body’s natural inflammation-resolution mechanisms without broadly suppressing the immune system.
• Blood pressure reduction: The compound helped lower blood pressure in hypertensive rats, showing a significant decrease in both systolic and diastolic readings compared to the control group.
• Vascular damage repair: It reduced aortic stiffness and alleviated scar tissue accumulation in the heart and kidneys, indicating its potential to reverse some structural changes associated with chronic hypertension.
• Precise targeting: The compound activates formyl peptide receptors, which are present on immune cells and tissue cells, helping the body terminate immune responses without the broad immunosuppression seen with traditional anti-inflammatory drugs.
Researchers explained that traditional anti-inflammatory drugs broadly target the immune system, which may lead to excessive suppression of immune responses and potentially adverse effects on blood pressure. In contrast, the new compound enhances the body’s natural mechanisms for resolving inflammation, potentially making it safer and more effective in the long term.
Study results also indicated that activating formyl peptide receptors may have additional benefits beyond lowering blood pressure, including improved kidney function and a reduced risk of developing hypertension-related kidney failure. This discovery could have significant implications for treating millions of patients who do not respond adequately to conventional antihypertensive medications.
The study concluded that activating formyl peptide receptors represents a promising therapeutic strategy for lowering blood pressure and reducing fibrosis associated with vascular and kidney diseases. However, researchers emphasized that the results are still in the experimental animal stage, and further clinical studies in humans are required before this compound can be approved as an available treatment. Subsequent research phases will need to evaluate the drug’s safety, appropriate dosages, and potential side effects in humans.
The research team hopes to begin clinical trials on humans in the coming years, after completing the necessary preclinical studies. If human trials confirm the compound’s efficacy, it could represent a breakthrough in the treatment of hypertension, particularly for patients who are resistant to or have contraindications for conventional therapies.
